What Сандостатин Treats: Main Uses and Benefits

The medication is relevant for easing challenging symptoms associated with hormonal hypersecretion disorders. It is commonly used across therapeutic domains where additional symptomatic support is needed. Its primary application is in the long-term management of Acromegaly and the symptomatic control of specific Neuroendocrine Tumors (NETs), including those causing Carcinoid Syndrome and VIPomas.

Control of Chronic and Acute Symptoms

The therapeutic application is primarily used to help manage symptoms related to systemic imbalance in Acromegaly and to address disruptive symptom clusters in NETs. This provides supportive relief when symptoms interfere with routine activities, such as addressing the challenging frequency of severe diarrhea and flushing episodes. It is also considered relevant when supportive symptom management is appropriate in acute scenarios, such as helping to support the patient during a severe event like a Carcinoid Crisis.

“The application is relevant where there is a need for supportive assistance with systemic imbalance, helping patients cope more steadily with symptom fluctuations.”

This assists with maintaining functional stability during difficult episodes, supporting the patient during episodes of heightened discomfort.

---

Quick Fact: Relief for Hormonal Overactivity

Symptom Domain	General Benefit Provided
Systemic Imbalance (GH/IGF-1 Excess)	Supports general well-being and assists with functional stability during symptomatic periods.
Gastrointestinal/Vasoactive Distress (NETs)	Contributes to easing the overall symptom load by addressing severe symptoms.
Acute Crisis/Hemorrhage (e.g., Varices)	Provides supportive relief and assists with maintaining functional stability during difficult, acute episodes.

Eligibility Scope: Official Regulatory Information

The population eligibility for Сандостатин (Octreotide) is strictly defined by regulatory documents, distinguishing between absolute prohibitions and conditional use requirements.

Contraindications and Prohibitions

Use is strictly contraindicated in patients with a known hypersensitivity to octreotide or any of the product’s excipients. Furthermore, the medicine is not recommended for patients who are breastfeeding. Use during pregnancy is also generally not recommended unless considered clearly necessary. Women of child-bearing potential must be advised to use adequate contraception, as fertility may be restored during treatment.

Age and Conditional Eligibility

The primary established population is adults (18 years and older). Use in pediatric patients is restricted as safety and efficacy have not been fully established. Conditional eligibility applies to patients with renal impairment or hepatic impairment, as drug clearance may be affected and the initial dose may require adjustment. Additionally, close monitoring is a prerequisite for continued eligibility in patients with pre-existing cardiac function abnormalities, diabetes mellitus (due to effects on glucose metabolism), and to assess for the formation of gallstones (cholelithiasis).

Interactions with other medicines and products

Octreotide has officially documented interaction patterns that are defined by its pharmacological and pharmacokinetic effects, as specified in regulatory labeling.

Drug-Drug Interaction Restrictions

Co-administration with medicines that prolong the QTc interval is formally contraindicated due to the risk of additive pharmacodynamic effects on cardiac conduction. Specific examples include certain antiarrhythmics like quinidine and sotalol. Dose adjustments and close monitoring are required when Octreotide is used with other medicinal products that cause bradycardia or with antidiabetic agents (including insulin and oral agents) because Octreotide alters glucose regulatory hormones.

Pharmacokinetic Effects on Co-administered Drugs

Octreotide may alter the systemic concentration of several co-administered medicines. The exposure (plasma levels) of agents such as Cyclosporine and Digoxin may be decreased, while the exposure of Bromocriptine may be increased. Increased caution is required when co-administering Octreotide with drugs primarily metabolized by CYP3A4 that possess a narrow therapeutic index.

Other Documented Interactions and Constraints

A mandatory timing rule requires that the long-acting formulation (SANDOSTATIN LAR DEPOT) be discontinued at least four weeks prior to the administration of Lutetium Lu 177 Dotatate Injection. Additionally, Octreotide has been associated with decreased Vitamin B12 levels. Regulatory documents also note that Octreotide's clearance is reduced in patients with renal impairment and its half-life increased in hepatic impairment.

Сандостатин (octreotide) functions as a synthetic agonist of the naturally occurring peptide hormone somatostatin. Its biological targets are the somatostatin receptors (SSTRs), which are G protein-coupled receptors. Octreotide exhibits its highest binding affinity for the SSTR2 and SSTR5 subtypes, followed by SSTR3, and low affinity for SSTR1 and SSTR4.

Upon binding and activation, the occupied SSTRs couple primarily to inhibitory Gi proteins (Gi). This coupling initiates an intracellular signaling cascade by inhibiting the enzyme adenylyl cyclase (AC). The resulting molecular consequence is a reduction in the intracellular concentration of cyclic adenosine monophosphate (cAMP).

This downstream cascade leads to the modulation of ion channels, specifically the inhibition of voltage-dependent calcium channels and the stimulation of G protein-regulated inward-rectifier potassium channels (Kir). The overall intracellular effect is membrane hyperpolarization and a decrease in intracellular calcium influx, which suppresses the process of exocytosis.

At the system level, this mechanism results in the broad inhibition of neuroendocrine and exocrine secretion, including the release of various hormones such as Growth Hormone (GH), insulin, glucagon, and multiple gastrointestinal peptides. Furthermore, octreotide promotes anti-proliferative cellular processes through the activation of phosphotyrosine phosphatase, thereby dephosphorylating and inhibiting growth factor signaling pathways, and through mechanisms involving the induction of pro-apoptotic signals.

Sandostatin (Octreotide) is a prescription medication administered by injection. It is available in two formulations: a short-acting solution for daily use and a long-acting release (LAR) depot for monthly use.

Administration and Dosing

Formulation	Route of Administration	Dosing Frequency	Key Instruction
Sandostatin Injection	Subcutaneous (SC) or Intravenous (IV)	Multiple times daily (2 to 4 doses)	Injection sites should be systematically rotated to minimize injection site pain.
Sandostatin LAR Depot	Deep Intramuscular (IM) injection into the gluteal region	Typically once every 4 weeks	Must be administered by a trained healthcare provider immediately following reconstitution.

The dosage and administration route are determined by the treating physician based on the patient's condition (e.g., acromegaly, carcinoid tumors, VIPomas) and individual response. Initial treatment often begins with the short-acting formulation to assess tolerance and response before switching to the long-acting depot form.

Preparation and Storage

• Temperature: Before administration, the medication should be removed from the refrigerator and allowed to warm to room temperature naturally. Do not apply heat to warm the medication, as this can compromise its integrity.
• Inspection: The solution must be visually inspected before use for particulate matter or discoloration; discard if either is present.
• Storage: Unopened Sandostatin should be stored in the refrigerator, protected from light, and not frozen.

It is essential to follow the specific instructions and schedule provided by your healthcare professional and to never adjust the dose without their guidance.

Research Evidence / Overview of Studies for Сандостатин

Evidence for Use in Managing Acromegaly

Research into Octreotide for Acromegaly—a condition characterized by the overproduction of Growth Hormone (GH) and Insulin-like Growth Factor-1 (IGF-1)—has been studied for many years. The core evidence is drawn from short-term Randomized Controlled Trials (RCTs), where patients were randomly assigned to receive the medication or a placebo or other active treatments. These studies were used in research exploring how symptoms change over time when their GH and IGF-1 levels were monitored.

The main findings described patterns related to the achievement of biochemical control in the body in the study populations, meaning that the levels of GH and IGF-1 were brought down to predefined ranges. Studies observed that this achievement of control was often monitored alongside changes in patient-reported outcomes related to physical discomfort and systemic imbalance, such as headaches, joint pain, and excessive perspiration. Furthermore, trials monitored the size of the tumors in the pituitary gland.

Evidence for Delayed Neuroendocrine Tumor Progression

Beyond symptom control, research examined the Progression-Free Survival (PFS) outcome and the tumor size in certain NETs. The key evidence in this area comes from large, prospective, Randomized, Placebo-Controlled Trials that specifically focused on the long-term course of the disease. The primary outcome studied was Progression-Free Survival (PFS), which is a measure of the time that passes before the tumor grows or the disease shows signs of worsening.

Studies monitored disease progression over defined time intervals. The primary outcome, Progression-Free Survival (PFS), was monitored in these trials, and research reported differences in the time before tumor growth between the monitored groups. However, this initial randomized research was primarily focused on midgut NETs. Findings for other types of NETs (such as those arising in the pancreas or lung) remain less consistently defined by large-scale RCTs.

What is Still Uncertain in the Research

Despite the established research base for the medication, the evidence highlights what is known and what is still uncertain across several areas.

One key limitation is that comparative evidence is lacking between the short-acting and long-acting formulations for managing acute, severe hormonal episodes. Furthermore, while the anti-proliferative effect was established for midgut NETs, subgroup findings are uncertain for other primary tumor sites. Finally, data for special groups, particularly children, remain insufficient, and research is ongoing to fully characterize long-term effects.

Common questions about Сандостатин (FAQ)

Q: What are the main conditions that Сандостатин is approved to treat?

Official regulatory documents state that this medicine is approved for the treatment of Acromegaly, a condition caused by excess Growth Hormone. It is also used to provide relief from severe symptoms associated with certain gastro-entero-pancreatic (GEP) neuroendocrine tumors, such as carcinoid tumors and VIPomas.

Q: Is it common to experience pain or irritation at the injection site, and how long does this usually last?

According to official product information, local pain and injection site reactions are a very common side effect, affecting more than 1 in 10 people. This discomfort is usually temporary; the pain, stinging, or burning sensation at the injection site is generally reported to subside within about 15 minutes.

Q: What are the most commonly reported side effects when first starting a course of Сандостатин?

Official documents summarizing clinical trials list common adverse reactions (those affecting more than 1 in 10 people) such as diarrhea, abdominal pain, nausea, headache, and hyperglycemia (high blood sugar). These are the side effects most frequently noted across the entire course of treatment, including the initial phase.

Q: How do healthcare providers monitor the effectiveness of the treatment (e.g., specific blood tests or scans)?

To check the treatment's effectiveness, healthcare providers monitor blood levels of certain hormones like Growth Hormone (GH) and IGF-1. Due to the medicine’s potential effects on the body, regulatory documents advise regular monitoring of thyroid function and periodic ultrasound checks of the gallbladder.

Q: How soon after the first injection can a person typically expect to see an effect on their symptoms?

For the short-acting injection, the maximum suppressive effect on hormone levels is typically seen within 30 minutes of administration. The therapeutic effect generally lasts for several hours, with documented action extending up to 12 hours.

Q: Is fatigue or tiredness a frequently reported side effect of using this medicine long-term?

According to official sources, fatigue (tiredness) and asthenia (weakness) are listed as common adverse reactions, affecting up to 1 in 10 people. In certain clinical trial populations, fatigue was reported more frequently, indicating it is a known concern.

Q: How long do initial digestive side effects, such as nausea or abdominal pain, typically persist after the injection?

Regulatory patient information notes that mild side effects, particularly common digestive issues like nausea or headache, are typically temporary. These effects are often expected to decrease or resolve as the patient’s body adjusts to the medication over time.

Q: Does the risk profile of side effects differ between the short-acting and LAR forms?

Studies comparing the two formulations indicate that the side effect profiles do differ in frequency. For instance, the rate of diarrhea is typically higher when using the short-acting injection, while the rate of constipation is reported to be higher with the long-acting (LAR) depot form.

Q: Are there common over-the-counter medications or supplements that are known to interact with this drug?

Official documents indicate that this medication may affect the body’s ability to absorb other orally administered drugs, including some over-the-counter medicines or supplements. It is also noted that it can affect the way certain compounds are broken down by the liver, which suggests general caution should be exercised when using other products.

Q: Is there long-term data available on the safety of using Сандостатин for many years?

The official regulatory information is based on long-term safety data from clinical trials. This data is used to inform specific warnings, such as the increased need for gallbladder monitoring after prolonged treatment of 12 months or longer.

Q: Does the medication have a known effect on a patient's overall body weight?

The medication can indirectly affect a patient’s weight due to its known effect on fat absorption, which may be associated with unintentional weight loss. Furthermore, because the medicine can cause hypothyroidism (a common side effect), weight gain is also a possibility that is monitored.

Q: Is it possible for a patient's symptoms to worsen initially before they begin to show improvement?

According to the product’s label, a temporary worsening (exacerbation) of symptoms may occur during the transition period when switching from the short-acting injection to the long-acting (LAR) depot form. This is especially noted if a patient does not continue the required short-acting injections for the specified initial period.

Q: What information is available regarding the joint and muscle pain reported by some patients during treatment?

Official regulatory information confirms that back pain is a common adverse reaction reported in clinical trials for some populations (affecting ge 1 in 10 people). While joint pain is also a symptom that the medicine is used to help manage in conditions like Acromegaly, musculoskeletal discomfort is a documented topic.

Q: What action should be taken if a patient misses a scheduled LAR injection appointment?

Official patient information indicates that if a scheduled long-acting (LAR) injection is missed, it is generally administered as soon as possible. Missing a dose may lead to a temporary reappearance of symptoms, and the normal dosing schedule is typically resumed after the missed dose is given.

Q: What are the potential effects of stopping treatment with Сандостатин suddenly?

Official regulatory guidance notes that stopping the medication abruptly is not recommended. Abrupt discontinuation of treatment carries the risk that underlying symptoms, such as those related to neuroendocrine tumors, may return or become worse.

Q: Is the sensation of dizziness a common temporary effect after receiving the injection?

Official product documentation lists the sensation of dizziness as a Common adverse reaction, meaning it may affect up to 1 in 10 people.

Q: Does this medicine have an effect on a patient’s ability to drive or operate machinery?

Official safety information states that the medicine itself has no or negligible direct effect on the ability to drive or operate machinery. However, it is noted that patients who experience side effects such as headache, dizziness, or tiredness may have a reduced ability to perform such tasks safely.

Q: Can the injection affect blood pressure levels?

Official clinical trial data indicates that changes in blood pressure may occur during treatment. Hypertension (high blood pressure) was reported as an adverse event in a significant portion of patients in some clinical studies. Bradycardia (slow heart rate) is also listed as a Common side effect.

The storage and disposal of Sandostatin (octreotide acetate) must strictly adhere to regulatory requirements to ensure product quality.

Mandatory Storage Conditions

Unopened product must be stored under refrigeration between 2 C to 8 C (36 F to 46 F). The product must not be frozen and must be protected from light by remaining in its original container. For daily use, it may be stored at room temperature (below 30 C) for a maximum of 14 days.

Stability and Disposal Rules

Multi-dose vials must be discarded 14 days after the first use. Any solution remaining in single-use ampules must be discarded immediately after opening. The medicine must be kept out of the reach and sight of children. All unused or expired product must be disposed of in accordance with local pharmaceutical waste requirements.